NSE: ROSSARI | BSE: 543213

Slowing Down Stock

Download real time

533.50 2.35 (0.44%)

High vol. this week

NSE 23 Jan, 2026 3:31 PM (IST)

2,954.7

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Search Inside the pdf :

Rossari Biotech Ltd.

21 Jan 2026

533.50

0.44%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

The near-term headwinds—muted domestic demand, elevated employee costs, and gestation-led pressure from new capacities—are likely to keep earnings growth and return ratios subdued over the next few quarters.

Deven Choksey decreased Buy price target of Rossari Biotech Ltd. to 637.0 on 21 Jan, 2026.

Rossari Biotech Ltd.

24 Oct 2025, 12:00AM

533.50

0.44%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

Rossari Biotech continues to execute well operationally, leveraging R&D intensity and export expansion to offset pricing headwinds.

Number of FII/FPI investors decreased from 55 to 49 in Dec 2025 qtr

Rossari Biotech Ltd.

25 Jul 2025, 12:00AM

533.50

0.44%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Deven Choksey

Rossari Biotech’s Q1FY26 revenue grew by 11.0% YoY (-6.2% QoQ) to INR 5,437 Mn., in-line with our estimates, the growth was entirely driven by volume expansion of 11.0% YoY.

Rossari Biotech has lost -25.56% in the last 6 Months

Rossari Biotech Ltd.

22 Oct 2024

533.50

0.44%

HPPC steady; outlook bright backed by capex, market gain; Buy

Buy: Rossari Biotech Ltd.

Target

Anand Rathi

We expect it is likely to deliver 18%/22%/25% revenue/EBITDA/PAT CAGRs over FY25-27 due to swelling demand, capacity expansion and mounting exports.

Number of FII/FPI investors decreased from 55 to 49 in Dec 2025 qtr

Rossari Biotech Ltd.

22 Oct 2024

533.50

0.44%

Rossari Biotech | Q2FY25 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC business and capex to drive growth

Rossari Biotech Ltd. has an average target of 637.00 from 1 broker.

Rossari Biotech Ltd.

21 Oct 2024

533.50

0.44%

Exports drive revenue growth

Hold: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY25 HPPC revenue growth (+6.2% YoY) was hurt from softer demand and restricted ethylene oxide (EO) capacity.

Rossari Biotech Ltd. has an average target of 637.00 from 1 broker.

Rossari Biotech Ltd.

13 Jun 2024

533.50

0.44%

Diversified business mix; no major China competition; initiating, with a Buy

Buy: Rossari Biotech Ltd.

Anand Rathi

Rossari Biotech is a leading specialty chemicals manufacturing company, focusing on four core chemistries of enzymes, silicones, acrylics and surfactants. It caters to industries such as home and personal care, and performance chemicals (HPPC), textile specialty chemicals (TSC) and animal health and nutrition (AHN) products

Rossari Biotech Ltd. average weekly volume is high.

Rossari Biotech Ltd.

01 May 2024

533.50

0.44%

Rossari Biotech | Q4FY24 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC and capex to drive growth

Rossari Biotech Ltd. is trading below all available SMAs

Rossari Biotech Ltd.

24 Jan 2024, 12:00AM

533.50

0.44%

Rossari Biotech | Q3FY24 Result Update

Buy: Rossari Biotech Ltd.

Edelweiss

HPPC business and capex to drive growth

Rossari Biotech Ltd. average weekly volume is high.

Rossari Biotech Ltd.

24 Oct 2023, 12:00AM

533.50

0.44%

Volume jumps at the cost of margins

Sell: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY24 HPPC revenue (+21% YoY) was led by a volume push which has hurt prices and margins. Despite rise in utilisation from 50-55% to >75%, EBITDA margin dipped 100bp QoQ to 13.1%. It has chosen to play volume game for FY24 to drive utilisation, and expects to improve margins as plant utilisations stabilise at higher levels, which in our view can cap return ratio in near term.

Number of FII/FPI investors decreased from 55 to 49 in Dec 2025 qtr

VOTE: Is Rossari Biotech Ltd. worth buying?

73 Votes:

Buy 89.04%

Sell 4.11%

Hold 6.85%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf